Adverse effect of verapamil in a patient with the Lambert-Eaton syndrome

Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments

Myasthenic syndromes are typically characterized by muscle weakness and increased fatigability due to an impaired transmission at the neuromuscular junction (NMJ). Most cases are caused by acquired autoimmune conditions such as myasthenia gravis (MG), typically with antibodies against the acetylcholine receptor (AChR). Different drugs are among the major factors that may complicate pre-existing autoimmune myasthenic conditions by further impairing transmission at the NMJ. Some clinical observations are substantiated by experimental data, indicating that presynaptic, postsynaptic or more complex pathomechanisms at the NMJ may be involved, depending on the individual compound. Most robust data exist for the risks associated with some antibiotics (e.g., aminoglycosides, ketolides, fluoroquinolones) and cardiovascular medications (e.g., class Ia antiarrhythmics, beta blockers). Apart from primarily autoimmune-mediated disorders of the NMJ, de novo myasthenic manifestations may also be triggered by medical treatments that induce an autoimmune reaction. Most notably, there is growing evidence that the immune checkpoint inhibitors (ICI), a modern class of drugs to treat various malignancies, represent a relevant risk factor to develop severe and progressive medication-induced myasthenia via an immune-mediated mechanism. From a clinical perspective, it is of utmost importance for the treating physicians to be aware of such adverse treatment effects and their consequences. In this article, we aim to summarize existing evidence regarding the key molecular and immunological mechanisms as well as the clinical implications of medication-aggravated and medication-induced myasthenic syndromes.

Respiratory failure in lambert-eaton myasthenic syndrome precipitated by calcium-channel blockers: report of a case and literature review

There have been a few reports in the literature documenting the effects of calcium-channel blockers in Lambert-Eaton myasthenic syndrome (LEMS). We report a case of a patient with LEMS who developed respiratory failure after administration of diltiazem and verapamil. A patient with LEMS, associated with small-cell carcinoma in remission, developed multifocal atrial tachycardia, necessitating the use of diltiazem and verapamil, which led to respiratory failure and intubation 5 days after admission. The patient was taken off all calcium-channel blockers and weaned off the respirator after 6 days. Oral time-release diltiazem was restarted without further exacerbation of LEMS. Most likely the combined use of two different calcium-channel blockers, verapamil and diltiazem, was responsible for this patient's respiratory failure. To date, 5 cases (2 patients with LEMS and 3 with myasthenia gravis) in which cardiac calcium-channel blockers had a definite detrimental effect have been reported.

Verapamil-associated cardiogenic shock in a 71-year-old man with myasthenia gravis: a case report

Introduction

Myasthenia gravis is a rare neuromuscular disorder associated with a reduction in the availability of acetylcholine receptors at the post-synaptic membranes of skeletal muscles. This is caused by the production of anti-acetylcholine receptor antibodies at the neuromuscular junction due to an autoimmune insult, leading to a compromised neuromuscular transmission. Verapamil can influence, in a dose-dependent fashion, the neuromuscular transmission in myasthenia gravis.

Case presentation

We report a 71-year-old Caucasian man with myasthenia gravis suffering from a cardiogenic shock following a single dose of verapamil. The patient had uncontrolled atrial fibrillation with a heart rate of 120 beats/min. Atenolol 100 mg was started. The next day, verapamil SR 240 mg was started. Two hours after the first dose of verapamil, the patient complained of weakness and dyspnea with signs of shock; his blood pressure was 70/50 mm Hg and heart rate at 101 beats/min. An echocardiogram showed diffuse hypokinesis of both ventricles with an ejection fraction of 20%. Cardiac catheterization was performed and coronary arteries appeared without significant stenosis, but there was a diffuse hypokinesis. Verapamil was stopped and the patient received intravenous glucagon and calcium chloride. Both the anti-acetylcholine receptor and anti-striated muscle antibodies tested positive. A few hours later, another echocardiogram showed an improvement in the ventricular function, which returned to normal five days later.

Conclusion

Caution is needed when administering verapamil to patients with myasthenia gravis, especially when the anti-acetylcholine receptor and anti-striated muscle antibodies titres are positive.

Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission

Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder in which autoantibodies apparently target the voltage-gated Ca2+ channels that regulate acetylcholine (ACh) release at motor nerve terminals. P/Q-type Ca2+ channels are primarily involved in ACh release at mammalian neuromuscular junctions. Passive transfer of LEMS to mice by repeated administration of plasma from LEMS patients reduces the amplitude of the perineurial P/Q-type current, and unmasks a dihydropyridine (DHP)-sensitive L-type Ca2+ current at the motor nerve terminal. The present study sought to determine if this DHP-sensitive component contributes to ACh release. Mice were treated for 30 days with plasma from healthy human controls or patients with LEMS. For some studies, diaphragms from naive mice were incubated with LEMS or control human plasma for 2 or 24 h. End-plate potentials (EPPs) and miniature end-plate potentials (MEPPs) were recorded from neuromuscular junctions in the hemidiaphragm. Treatment of mice with LEMS plasma evoked the characteristic electrophysiological signs of LEMS: reduced quantal content and facilitation of EPP amplitudes at high-frequency stimulation. Quantal content was also reduced in muscles incubated acutely with LEMS plasma. Nimodipine, a DHP-type blocker of L-type Ca2+ channels, did not significantly affect the quantal content of muscles treated for 2 or 24 h with either control or LEMS plasma, or following chronic treatment with control plasma. However, following 30 days treatment with LEMS plasma, nimodipine significantly reduced the remaining quantal content to 57.7 +/- 3.3 % of pre-nimodipine control levels. Thus, DHP-sensitive Ca2+ channels become involved in synaptic transmission at the mouse neuromuscular junction after chronic, but not acute treatment with LEMS plasma. However, reductions in quantal release of ACh occur even after very short periods of exposure to LEMS plasma. As such, development of the L-type Ca2+ channel contribution to ACh release during passive transfer of LEMS appears to occur only after quantal release is significantly impaired for an extended duration, suggesting that an adaptive response of the ACh release apparatus occurs in LEMS.

Remote neurologic manifestations of cancer

Paraneoplastic disorders may affect any part of the central or peripheral nervous systems. Although relatively uncommon, these disorders are a significant cause of neurologic morbidity for cancer patients. At least some paraneoplastic syndromes are believed to be caused by an autoimmune reaction against shared tumor-neural antigens. This article summarizes the clinical features of paraneoplastic disorders, the current evidence for autoimmunity, and guidelines for diagnosis and treatment.

Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis

The effect of intravenous injection of propranolol, verapamil, terbutaline, calcium, and edrophonium on neuromuscular transmission has been studied with repetitive nerve stimulation and clinical tests in 10 patients with myasthenia gravis (MG). The drugs were given intravenously in doses commonly used in clinical practice. Only minor clinical effects were noted except for edrophonium. The mean decrement of the deltoid muscle was not significantly changed after injection of propranolol (before 31%, 15 min after injection 27%) and verapamil (before 29%, 15 min after injection 26%). Terbutaline applied after propranolol and calcium applied after verapamil improved the decrement substantially. Edrophonium applied after propranolol or verapamil also greatly improved the decrement. We conclude that there is no rapid deterioration of neuromuscular transmission in patients with moderately severe MG after injections with therapeutic doses of propranolol and verapamil. However, we do not know if the most severely disabled MG patient could have reacted otherwise. We consider that, in cardiovascular emergencies, propranolol and verapamil may be used even in severe MG but with resuscitation equipment as well as specific antidotes available.

Variable effect of calcium channel blockers on the decremental response in experimental autoimmune myasthenia gravis

We tested the effect of intravenous administration of verapamil and nimodipine on the decremental response in rabbits with experimental autoimmune myasthenia. Nimodipine produced an immediate augmentation of the decremental response to 3-Hz nerve stimulation, which lasted about 30 min. In contrast, verapamil caused marked amelioration of the decrement beginning 30 min after injection. Our findings are consistent with previous reports suggesting that verapamil has a presynaptic effect of enhanced acetylcholine release at the neuromuscular junction. Since evaluation of a drug effect in vivo in animals with experimental autoimmune myasthenia gravis may be more pertinent to its effect on patients with myasthenia gravis (MG), verapamil might prove to be safer in MG than nimodipine. However, due to the additional effects of calcium channel blockers, the safety of their use in myasthenia gravis cannot be inferred from the experimental results.

Adverse effect of verapamil in myasthenia gravis

Verapamil, a class IV anti-arrhythmic drug that blocks voltage-dependent calcium channels in cardiac and smooth muscle, also has effects on presynaptic and postsynaptic voltage-dependent calcium channels at the neuromuscular junction. In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.

Electrical stimulation of nerve regeneration in the rat: the early effects evaluated by a vibrating probe and electron microscopy

This study examines the effect of applied d.c. electric fields on nerve regeneration following injury to the rat sciatic nerve using the circularly vibrating probe and electron microscopy. The transected and treated nerve which received a d.c. electrical stimulator (0.6 mu A) was compared with untreated transected and crushed nerves. At one week postoperative, the probe was used to measure in vivo the current density along the nerve length. All nerves studied had a proximal peak at the lesion site and a second peak at varying distal locations: crushed/untreated (13.3 mm), transected/untreated (9.7 mm) and transected/treated (16.3 mm). A significant difference (69%) between the distal peak distances in the two transection groups suggests that the electrical treatment enhanced the progress of nerve regeneration. There were no significant differences between the mean peak amplitudes (1.6-2.2 mu A/cm2). Applied verapamil reduced the peaks, suggesting they are associated in part with a calcium-dependent current. Electron microscopy at selected nerve regions indicated that the peaks correspond to regenerating axonal growth cones. The results suggest the potential clinical application of d.c. electric fields in the treatment of nerve injuries.

Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome

Among 13 patients with the Lambert-Eaton myathenic syndrome (LEMS), three different patterns on the repetitive nerve stimulation test were observed at the time of initial testing. Type 1 pattern, seen in one patient, had low normal CMAP amplitude, decremental response at the low rate of stimulation (LRS), and relatively normal response at the high rate of stimulation (HRS). Type 2, seen in nine patients, had the classical triad: low CMAP amplitude, decremental response at LRS, and incremental response at HRS. Type 3, seen in three patients, showed low CMAP amplitude, decremental response at LRS, and initial decremental response at HRS. We believe that these three patterns represent different degrees of blocking in LEMS, from the mildest in type 1 to the most severe in type 3. Since types 1 and 3 can be misinterpreted as myasthenia gravis patterns, they must be recognized in LEMS and an incremental response documented by prolonged stimulation at HRS.